Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Holdings Raised by Diversified Trust Co

Diversified Trust Co lifted its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 12.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 175,741 shares of the company’s stock after purchasing an additional 20,091 shares during the quarter. Diversified Trust Co’s holdings in Xeris Biopharma were worth $388,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Quarry LP bought a new stake in shares of Xeris Biopharma during the fourth quarter valued at about $47,000. Invenomic Capital Management LP bought a new stake in shares of Xeris Biopharma during the fourth quarter valued at about $1,336,000. CenterBook Partners LP bought a new stake in shares of Xeris Biopharma during the fourth quarter valued at about $260,000. Stonepine Capital Management LLC raised its stake in shares of Xeris Biopharma by 0.4% during the fourth quarter. Stonepine Capital Management LLC now owns 5,937,000 shares of the company’s stock valued at $13,952,000 after purchasing an additional 21,628 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Xeris Biopharma by 53.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 27,848 shares of the company’s stock valued at $65,000 after purchasing an additional 9,733 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on XERS. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Xeris Biopharma in a research report on Friday, May 31st. Finally, Oppenheimer began coverage on shares of Xeris Biopharma in a research report on Thursday, March 28th. They issued an “outperform” rating and a $5.00 price target on the stock.

Xeris Biopharma Trading Up 1.0 %

Shares of Xeris Biopharma stock opened at $2.08 on Friday. The company’s 50-day moving average price is $2.06 and its two-hundred day moving average price is $2.29. The stock has a market cap of $308.38 million, a PE ratio of -4.43 and a beta of 2.72. Xeris Biopharma Holdings, Inc. has a 52 week low of $1.46 and a 52 week high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). The company had revenue of $40.64 million during the quarter, compared to analysts’ expectations of $41.56 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 37.58%. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.